CJC-1295 No DAC vs CJC-1295 With DAC: Research Differences Explained

CJC-1295 No DAC and CJC-1295 with DAC are often discussed as if the difference were merely a label variation. Scientifically, the distinction is much more important. The albumin-binding Drug Affinity Complex changes the molecular structure, persistence and analytical behaviour of the peptide, so data from the long-acting DAC form should not automatically be applied to the No-DAC form.

This guide compares the two research categories and explains why accurate naming matters for laboratory records, literature interpretation and Certificate of Analysis review.

The Common Starting Point: GHRH Biology

Both categories are discussed within the broader field of growth-hormone-releasing-hormone analogue research. GHRH is a hypothalamic peptide that interacts with the GHRH receptor on pituitary somatotroph cells and participates in physiological regulation of pulsatile growth hormone secretion.

Shorter GHRH fragments, particularly GHRH(1-29)-NH2, have been studied in humans and can retain biological activity. Medicinal-chemistry programmes have used amino-acid substitutions and other structural changes to alter stability, receptor activity and persistence.

What Is CJC-1295 With DAC?

The CJC-1295 molecule characterised in the best-known human clinical paper is a long-acting GHRH analogue containing a Drug Affinity Complex. The DAC chemistry was designed to react with albumin in circulation, producing an albumin-associated form with much greater persistence than unmodified GHRH fragments.

In healthy adults, Teichman and colleagues reported sustained pharmacodynamic effects after administration of this long-acting CJC-1295 and estimated a half-life of approximately 5.8–8.1 days under the study conditions. That is one of the reasons the name CJC-1295 became strongly associated with prolonged activity in the literature.

What Is CJC-1295 No DAC?

The term CJC-1295 No DAC is commonly used commercially for a short-acting modified GHRH(1-29) analogue, also referred to as Modified GRF (1-29) or Mod GRF (1-29). As the name states, the albumin-binding DAC modification is absent.

Because the defining long-acting chemical feature has been removed, the No-DAC material should not be described using the multi-day pharmacokinetic values established for DAC-containing CJC-1295. The most defensible scientific approach is to treat the No-DAC material as its own molecular record and verify the exact sequence and mass for the batch being studied.

Why Albumin Binding Changes Peptide Behaviour

Albumin is a highly abundant plasma protein with a comparatively long circulatory residence time. Medicinal chemists can exploit albumin association to reduce rapid renal clearance and decrease immediate exposure of a peptide to some degradative processes.

Adding an albumin-binding group therefore does more than make a peptide “longer acting” in a general sense. It changes molecular mass, hydrophobicity, protein binding, distribution, clearance and chromatographic behaviour. Those changes can be measured analytically and can influence how a molecule behaves in experimental systems.

Why GHRH(1-29) Research Is Relevant to the No-DAC Form

Human research predating CJC-1295 showed that the N-terminal 1-29 region of GHRH can retain growth-hormone-releasing activity. GHRH(1-29)-NH2 and defined substituted analogues were investigated in normal volunteers, demonstrating that short GHRH fragments can be biologically active while also showing relatively rapid clearance.

For example, research on D-Ala2-GHRH(1-29)-NH2 demonstrated that even a single substitution could reduce metabolic clearance and modestly extend plasma disappearance time. This illustrates a fundamental peptide-chemistry principle: small structural changes can measurably alter pharmacokinetics.

Side-by-Side Scientific Comparison

  • Core research pathway: both are associated with GHRH-receptor agonism.
  • DAC: present in the long-acting form; absent in the No-DAC form.
  • Albumin association: intentionally engineered into the DAC form.
  • Human multi-day half-life evidence: established for the DAC-linked CJC-1295 studied clinically, not for generic No-DAC material.
  • Common No-DAC terminology: Modified GRF (1-29) / Mod GRF (1-29).
  • Analytical identity: should be established separately because molecular structure and mass differ.

Do the Two Forms Have the Same HPLC Retention Time?

No assumption should be made that they will. Lipophilicity, chemical modifications and molecular structure affect interaction with reverse-phase chromatography systems. A DAC-containing molecule and a No-DAC molecule can therefore exhibit different retention behaviour under the same HPLC conditions.

Retention time itself is also method-dependent. Column chemistry, gradient, mobile phase and detector configuration influence where a compound appears. Identification should use appropriate standards and complementary analytical evidence rather than relying on retention time alone.

Mass Spectrometry and the DAC Question

Mass spectrometry can provide powerful evidence when distinguishing the two forms because the expected molecular masses are different. A report described merely as “CJC-1295 LC-MS” is incomplete if it does not make clear which molecular form was expected and tested.

A strong analytical record should state the material identity unambiguously and show that the observed mass information is consistent with the specified molecule.

Why Certificates of Analysis Should State “DAC” or “No DAC”

A batch COA should make the molecular form clear. Ideally, a laboratory record can connect the exact product name, DAC status, batch number, analytical method and result without requiring interpretation from marketing terminology.

If a vial is labelled CJC-1295 No DAC but the supporting analytical document simply states CJC-1295, clarification is warranted. The ambiguity matters because the two forms are not analytically interchangeable.

For broader guidance, see Certificate of Analysis Explained and the COA Library.

Common Nomenclature Errors

Error 1: Applying the DAC half-life to No-DAC material

The multi-day half-life reported in the major CJC-1295 human study relates to the long-acting DAC molecule. It should not be copied onto a No-DAC product description.

Error 2: Treating “Modified GRF (1-29)” and every “CJC-1295” listing as automatically identical

Commercial naming varies. Exact sequence and molecular specification are more reliable identifiers than a marketplace title.

Error 3: Treating purity as identity

A strong main HPLC peak does not by itself prove whether a sample is DAC or No DAC. Molecular identity requires appropriate analytical evidence.

Error 4: Assuming a COA from one form verifies the other

It does not. Analytical documentation should correspond to the exact molecule and production batch.

How to Document the Material in a Research Record

A rigorous record should capture the full name used on the vial, whether DAC is present, the nominal quantity, batch number, COA reference and the analytical techniques used. If the material is called Modified GRF (1-29), record that terminology rather than silently replacing it with the name of the DAC-linked molecule.

Frequently Asked Questions

What does DAC stand for?

DAC means Drug Affinity Complex. In CJC-1295 research it refers to chemistry designed to create prolonged association with circulating albumin.

Does No DAC mean the peptide is inactive?

No. The term refers to the absence of the albumin-binding DAC modification, not to whether a GHRH analogue can interact with the GHRH receptor.

Why is Modified GRF (1-29) called CJC-1295 No DAC?

That naming is widespread in the research-material market, although it can obscure important chemical distinctions. For rigorous documentation, the exact molecular specification should take priority over marketplace shorthand.

Which form was used in the famous multi-day CJC-1295 human study?

The long-acting DAC-containing CJC-1295 molecule.

Selected Scientific References

Related Research Resources

This article is provided for laboratory, analytical and scientific education only. It does not provide dosing, administration, injection, therapeutic or personal-use guidance.

Back to blog